Conference Description

Online registration for this activity is closed. Please call (954) 723-0057 for more information.

This CME activity is open only to Rheumatologists and nurse practitioners and physician assistants who are working in a Rheumatology practice.

September 8, 2007 Westin Diplomat Resort & Spa 3555 South Ocean Drive Hollywood, Florida Tell a friend about this conference Download the brochure for this conference CME Credits 6.8* Nonrefundable registration fee: $0. Target Audience: Rheumatologists Learning Objectives: The intimate setting of this conference will maximize learning and discussion and will enable rheumatologists to learn first hand from thought leaders in their field. Among the proposed topics and objectives will be to: compare oral and intravenous therapies in the management of osteoporosis discuss recent updates in giant cell arteritis discuss new concepts in the evaluation and management of the anti-phospholipid syndrome describe the importance of B-cell therapies in the management of RA explain the appropriate use of viscosupplementation for the treatment of osteoarthritis describe new findings in the use of biologic therapy in the treatment of ankylosing spondylitis explain the use of second signal inhibitor, abatacept, in treating RA describe new findings in the management of psoriatic arthritis discuss the use of biologic therapy in treating autoimmune disorders other than RA Agenda: Saturday, September 8, 2007 7:30-8:10    Registration and Continental Breakfast Welcome—Charles Kahn, MD and Wayne Riskin, MD 8:10-9:00    Osteoporosis: Comparison of Oral Therapy and Intravenous Therapy Nelson Watts, MD 9:00-9:50    Giant Cell Arteritis: Recent updates Carol Langford, MD, MHS 9:50-10:10    Morning Break 10:10-11:00    Rheumatoid Arthritis: Focus on B-cell Therapy: Emerging and existing theory Daniel E. Furst, MD 11:00-11:50    Viscosupplementation: When and where? David D. Waddell, MD 11:50-1:00    Lunch 1:00-1:50    Ankylosing Spondylitis: Update on biologic therapy Muhammed Khan, MD 1:50-2:40    Second Signal Inhibitor: Abatacept Alan Brown, MD 2:40-3:00    Afternoon Break 3:00-3:50    Psoriatic Arthritis: An update Alan Brown, MD 4:00-4:50    Using Biologics in the Treatment of Autoimmune Disorders Other than Rheumatoid Arthritis Robert A. Snyder, MD, and Wayne Schonfeld, MD 4:50-5:00    Closing Remarks Charles Kahn, MD and Wayne Riskin, MD Faculty: Alan Brown, MD Associate Professor of Medicine Division of Rheumatology and Immunology Vice Chairman for Education, Department of Medicine Medical University of South Carolina Daniel E. Furst, MD Carl M. Pearson Professor of Medicine at the University of California in Los Angeles Director, Arthritis Clinical Research in the Division of Rheumatology at UCLA Muhammed Asim Khan, MD, MACP, FRCP Professor of Medicine, Case Western Reserve University, Cleveland, Ohio Staff Physician, Department of Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, Ohio Carol Langford, MD, MHS Director, Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases Cleveland Clinic Foundation Wayne Schonfeld, MD, FACP, FACG Gastroenterology Associates of Hollywood Hollywood, FL Robert A. Snyder, MD Dermatology Consultants of Broward Voluntary Associate Professor of Dermatology University of Miami David D. Waddell, MD Orthopedic Specialists of Louisiana Clinical Associate Professor of Orthopedics LSU Health Sciences Center Nelson Watts, MD Professor of Medicine Director, Osteoporosis and Bone Health Program University of Cincinnati Program Planning Committee: Charles Kahn, MD, FACP, FACR Wayne G. Riskin, MD, FACP, FACR Elaine Kahn, MSN, ARNP *Continuing Education Information This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. UMMS is accredited by ACCME to provide continuing medical education for physicians. UMMS designates this continuing medical education activity for 6.8 credit hours in Category I toward the Physicians Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 6.8 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity. In accordance with the Standards of the Accreditation Council for Continuing Medical Education (ACCME) and the guidelines of the Association of American Medical Colleges (AAMC), it is the policy of the University of Massachusetts Medical School to disclose whatever interest or affiliation a speaker might have with any commercial organization whose products or services are related to the subject matter being presented. Such disclosure will be made available on the day of the program. This program was supported through educational grants from the following companies: Abbott Laboratories, Inc., Actelion, Amgen, Bristol-Myers Squibb, Centocor, Ferring Pharmaceuticals, Genentech and Biogen Idec, Procter and Gamble, Sanofi-Aventis, Wyeth.